TransThera Sciences (Nanjing), Inc. is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapies. It focuses on addressing unmet needs in oncology, inflammatory diseases, and cardiometabolic conditions through a fully integrated in-house R&D system. The company's core product, Tinengotinib (TT-00420), is a unique multi-targeted kinase inhibitor targeting key pathways and is currently in two pivotal registrational clinical trials for cholangiocarcinoma treatment following prior FGFR inhibitor therapy, one conducted in China. Its pipeline includes five clinical-stage candidates and one preclinical asset, such as TT-00434 and TT-00920, emphasizing tumor and immunity fields. Operating in the biotechnology sector with 121 employees, TransThera Sciences (Nanjing), Inc. plays a significant role in advancing novel treatments, contributing to global efforts in precision medicine and targeted therapies for hard-to-treat diseases.